Anti-HPV16 antibody titers prior to an incident cervical HPV16/31 infection

Ana Gradissimo, Viswanathan Shankar, Fanua Wiek, Lauren St Peter, Yevgeniy Studentsov, Anne Nucci-Sack, Angela Diaz, Sarah Pickering, Nicolas F. Schlecht, Robert D. Burk

Research output: Contribution to journalArticlepeer-review

1 Scopus citations


The goal of this study was to investigate the serological titers of circulating antibodies against human papillomavirus (HPV) type 16 (anti-HPV16) prior to the detection of an incident HPV16 or HPV31 infection amongst vaccinated participants. Patients were selected from a prospective post-HPV vaccine longitudinal cohort at Mount Sinai Adolescent Health Center in Manhattan, NY. We performed a nested case–control study of 43 cases with incident detection of cervical HPV16 (n = 26) or HPV31 (n = 17) DNA who had completed the full set of immunizations of the quadrivalent HPV vaccine (4vHPV). Two control individuals whom had received three doses of the vaccine (HPV16/31-negative) were selected per case, matched on age at the first dose of vaccination and follow-up time in the study: a random control, and a high-risk control that was in the upper quartile of a sexual risk behavior score. We conducted an enzyme-linked immunosorbent assay (ELISA) for the detection of immunoglobulin G (IgG) antibodies specific to anti-HPV16 virus-like particles (VLPs). The results suggest that the average log antibody titers were higher among high-risk controls than the HPV16/31 incident cases and the randomly selected controls. We show a prospective association between anti-HPV16 VLP titers and the acquisition of an HPV16/31 incident infection post-receiving three doses of 4vHPV vaccine.

Original languageEnglish (US)
Article number1548
Issue number8
StatePublished - Aug 2021


  • Antibody titer
  • HPV16
  • Papillomavirus
  • Quadrivalent vaccine
  • VLP

ASJC Scopus subject areas

  • Infectious Diseases
  • Virology


Dive into the research topics of 'Anti-HPV16 antibody titers prior to an incident cervical HPV16/31 infection'. Together they form a unique fingerprint.

Cite this